Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 19/20 | 0.48 |
| ▸ | CYBB | P04839 | 9/20 | 0.47 |
| ▸ | NOX5 | Q96PH1 | 1/20 | 0.47 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5206891 | 0.78 | HTR1D (0.56) | NCF1CYBBNOX5 | |
| SCHEMBL5211096 | 0.74 | NCF1 (0.48) | NCF1CYBBNOX5 | |
| SCHEMBL5211140 | 0.72 | HTR1A (0.45) | NCF1CYBBNOX5 | |
| SCHEMBL2191686 | 0.72 | GRM5 (0.58) | GRM5KCNH2 | |
| SCHEMBL31556373 | 0.72 | GRM5 (0.58) | GRM5KCNH2 | |
| SCHEMBL23412330 | 0.70 | NCF1 (0.86) | NCF1CYBBNOX5 | |
| SCHEMBL5214060 | 0.70 | NCF1 (0.42) | NCF1CYBBNOX5 | |
| SCHEMBL22559518 | 0.69 | CTSS (0.40) | GRM5KCNH2 | |
| SCHEMBL5181894 | 0.68 | SOS2 (0.56) | GRM5KCNH2 | |
| SCHEMBL2204553 | 0.68 | HTR1B (0.67) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1480972-B1 | COMPOUNDS POSSESSING AFFINITY AT 5HT1-TYPE RECEPTORS AND USE THEREOF IN THERAPY OF CNS DISORDERS | GLAXO GROUP LTD (GB) | 2007-04-11 | — | — | EP | disclosed |
| US-20050107410-A1 | Compound possessing affinity at 5ht1-type receptors and use thereof in therapy of cns disorders | GLAXO GROUP LIMITED (GB) | 2005-05-19 | — | — | US | disclosed |
| EP-1480972-A2 | COMPOUNDS POSSESSING AFFINITY AT 5HT1-TYPE RECEPTORS AND USE THEREOF IN THERAPY OF CNS DISORDERS | GLAXO GROUP LIMITED (GB) | 2004-12-01 | — | — | EP | disclosed |
| WO-2003068760-A2 | COMPOUNDS POSSESSING AFFINITY AT 5HT1-TYPE RECEPTORS AND USE THEREOF IN THERAPY OF CNS DISORDERS | GLAXO GROUP LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107410-A1 | Compound possessing affinity at 5ht1-type receptors and use thereof in therapy of cns disorders | CNR1, HTR5A, HTR1A | NCF1 1554/4885CYBB 1335/4885NOX5 932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.